Advanced Proteome Therapeutics (TSXV:APC.H) Interest Expense : C$-0.05 Mil (TTM As of Apr. 2023)

View and export this data going back to 1989. Start your Free Trial

What is Advanced Proteome Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Advanced Proteome Therapeutics's interest expense for the three months ended in Apr. 2023 was C$ -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Apr. 2023 was C$-0.05 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Advanced Proteome Therapeutics's Operating Income for the three months ended in Apr. 2023 was C$ -0.20 Mil. Advanced Proteome Therapeutics's Interest Expense for the three months ended in Apr. 2023 was C$ -0.01 Mil. Advanced Proteome Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Advanced Proteome Therapeutics Interest Expense Historical Data

The historical data trend for Advanced Proteome Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Proteome Therapeutics Interest Expense Chart

Advanced Proteome Therapeutics Annual Data

Trend

Jul13

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Interest Expense

Get a 7-Day Free Trial

-0.09

-0.03

-0.04

-0.03

-0.04

Advanced Proteome Therapeutics Quarterly Data
	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23
Interest Expense	Get a 7-Day Free Trial															-0.01	-0.01	-0.02	-0.02	-0.01

Advanced Proteome Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Apr. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.05 Mil.

Advanced Proteome Therapeutics (TSXV:APC.H) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Advanced Proteome Therapeutics's Interest Expense for the three months ended in Apr. 2023 was C$-0.01 Mil. Its Operating Income for the three months ended in Apr. 2023 was C$-0.20 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Apr. 2023 was C$0.00 Mil.

Advanced Proteome Therapeutics's Interest Coverage for the quarter that ended in Apr. 2023 is calculated as

Advanced Proteome Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Advanced Proteome Therapeutics (TSXV:APC.H) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advanced Proteome Therapeutics Corp (TSXV:APC.H) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

0E81:Germany

Address

8337 Eastlake Drive, Suite 104, Burnaby, BC, CAN, V5A 4W2

Website

https://www.advancedproteome.com

Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.

Advanced Proteome Therapeutics (TSXV:APC.H) Headlines

No Headlines